Voxtalisib

Voxtalisib (XL-765, SAR245409) is a drug which acts as a dual inhibitor of the kinase enzymes phosphatidylinositol 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR). It is in clinical trials for the treatment of various types of cancer.^{[1][2][3][4][5]}

Voxtalisib

Identifiers
IUPAC name 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7-one
CAS Number	934493-76-2
PubChem CID	16123056
DrugBank	DB12400
ChemSpider	17279963
UNII	CVL1685GPH
ChEBI	CHEBI:124914
ChEMBL	ChEMBL3545366
Chemical and physical data
Formula	C13H14N6O
Molar mass	270.296 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCN1C2=NC(=NC(=C2C=C(C1=O)C3=CC=NN3)C)N
InChI InChI=1S/C13H14N6O/c1-3-19-11-8(7(2)16-13(14)17-11)6-9(12(19)20)10-4-5-15-18-10/h4-6H,3H2,1-2H3,(H,15,18)(H2,14,16,17) Key:RGHYDLZMTYDBDT-UHFFFAOYSA-N